

## **Product datasheet for TG309121**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **SQSTM1 Human shRNA Plasmid Kit (Locus ID 8878)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** SQSTM1 Human shRNA Plasmid Kit (Locus ID 8878)

Locus ID: 8878

Synonyms: A170; DMRV; FTDALS3; NADGP; OSIL; p60; p62; p62B; PDB3; ZIP3

**Vector:** pGFP-V-RS (TR30007)

E. coli Selection: Kanamycin

Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

**Components:** SQSTM1 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 8878).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.

RefSeq: NM 001142298, NM 001142299, NM 003900, NM 003900.1, NM 003900.3, NM 003900.4,

NM 001142298.1, NM 001142299.1, BC017222, BC017222.1, BC000951, BC001874, BC003139,

BC005857, BC019111, BC050631, BM800056

UniProt ID: Q13501

**Summary:** This gene encodes a multifunctional protein that binds ubiquitin and regulates activation of

the nuclear factor kappa-B (NF-kB) signaling pathway. The protein functions as a

scaffolding/adaptor protein in concert with TNF receptor-associated factor 6 to mediate activation of NF-kB in response to upstream signals. Alternatively spliced transcript variants encoding either the same or different isoforms have been identified for this gene. Mutations in this gene result in sporadic and familial Paget disease of bone. [provided by RefSeq, Mar

2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).